Kodiak Sciences Inc.
KOD
Rang in aandelen
#3086
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Aandeelprijs
$93.69
Marktkapitalisatie
$5.89B
Verandering (1 dag)
2.56%
Verandering (1 jaar)
429.32%
Land
US
Handel Kodiak Sciences Inc. (KOD)
Categorie
Healthcare
Aandelsplitsingen voor Kodiak Sciences Inc. (KOD)
Het aandeel Kodiak Sciences Inc. (symbool: KOD) heeft in totaal 1 splitsingen ondergaan.
De meest recente splitsing vond plaats op Feb 23, 2022.
Eén aandeel KOD dat vóór Feb 23, 2022 werd gekocht, staat nu gelijk aan 5 aandelen KOD.
De meest recente splitsing vond plaats op Feb 23, 2022.
Eén aandeel KOD dat vóór Feb 23, 2022 werd gekocht, staat nu gelijk aan 5 aandelen KOD.
Lijst van aandelen splitsingen
| Jaar | Splitsing | Vermenigvuldiging | Cumulatieve vermenigvuldiging |
|---|---|---|---|
| 2022-02-23 | 5:1 | x5 | x5 |
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aantal aandelen splitsingen | Cumulatieve vermenigvuldiging | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
